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Type 2 diabetes mellitus (T2DM) is a complex chronic disease affecting over 400 
million people worldwide. Managing T2DM and its associated complications in individual 
patient consultations poses substantial challenges to physicians due to limited time and 
resources and lack of access to multidisciplinary teams. Shared medical appointments 
(SMAs) are consecutive medical consultations provided by a physician in a group setting, 
where integrated medical care and patient education are delivered in a single session. 
SMAs allow physicians to deliver the same level of care to multiple patients at the same 
time, thereby maximizing available resources. However, the effectiveness and practicality 
of SMAs in the management of T2DM remains unknown. This narrative review summa-
rizes current and emerging evidence regarding the effectiveness of SMAs in improving 
clinical outcomes in patients with T2DM, as well as whether SMAs are associated 
with reduced costs and improved diabetes-related behavioral and lifestyle changes. 
An extensive literature search was conducted on major electronic databases including 
PubMed and Google Scholar using keywords, including SMAs, group visits, and T2DM 
to identify all studies of SMAs in patients with T2DM. Studies in type 1 diabetes or mixed 
or unspecified populations were excluded, as well as studies where SMAs did not involve 
a physician since these do not meet the classical definition of a SMA. Nineteen studies 
were identified and are included in this review. Overall, current evidence suggests that 
SMAs delivered regularly over time may be effective in improving glycemic outcomes, 
diabetes knowledge, and some diabetes-related behaviors. However, the main limitation 
of existing studies was the paucity of comparisons with standard care which limits the 
ability to draw conclusions regarding whether SMAs are superior to standard care in 
T2DM management. Moreover, the small number of studies and substantial heteroge-
neity in study designs, populations, and interventions creates difficulties in establishing 
the practicality and efficiency of SMAs in the clinical care setting. We conclude that there 
remains a need for larger studies to identify populations who may or may not benefit from 
the SMA model of care and to clarify the potential benefits and barriers to implementing 
SMAs into routine diabetes care.
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iNTRODUCTiON
Type 2 diabetes mellitus (T2DM) is a leading cause of morbidity 
and mortality, affecting 422 million adults globally (1). The preva-
lence of T2DM is rising in line with increased obesity (2), which 
today affects >1.9  billion adults worldwide (3). T2DM and its 
microvascular (retinopathy, nephropathy, neuropathy) and mac-
rovascular (cardiovascular, cerebrovascular, peripheral vascular) 
complications pose a substantial health and cost burden, account-
ing for >2 million deaths each year (4) and costing >$827 billion 
in direct costs annually (5). In view of the current T2DM burden, 
it is imperative to identify innovative and integrated models of 
care in order to improve disease management in clinical settings.
Currently, complex chronic diseases such as T2DM are 
managed through individual patient–doctor consultations (6). 
However, delivering high-quality evidence-based care in a one-
on-one setting is challenging due to the increasing number of 
patients with complex diseases, limited time for consultations, 
limited resources, and lack of access to multidisciplinary teams 
or integrated models of care (6). There is also no convincing 
evidence of the comparative effectiveness or otherwise of the 
one-on-one approach over any other. One approach which has 
been proposed to address these challenges is shared medical 
appointments (SMAs).
Originally developed by Caballero (6), SMAs are defined as: 
“…consecutive individual medical visits carried out in a supportive 
group setting of similar patients where all can listen, interact, and 
learn.” SMAs are group or cluster medical consultations (7), 
carried out sequentially, where approximately 8–15 patients 
with the same chronic condition are seen by a physician and an 
interdisciplinary team of health-care professionals over a 60- to 
120-min time period (8). This allows physicians to deliver the 
same level of care to multiple patients at the same time, thereby 
maximizing available resources (6). SMAs must involve a general 
practitioner or physician (GP) and are typically facilitated by a 
nurse practitioner or other allied health professional (9). SMAs, 
therefore, differ from disease-specific support groups or group 
education sessions in that provision of medical care by a quali-
fied physician (including diagnostic and laboratory assessments, 
prescriptions, and medical reviews, treatment, and management) 
is provided within the SMA care paradigm (10). Following the 
physician consultation, patients may engage with nurses or allied 
health professionals to discuss various topics related to their 
chronic disease, and an educational component is often held as a 
talk, discussion, or audio-visual presentation, generally without 
the doctor present (6). The concept of SMAs is based on providing 
integrated medical care and patient education, making it an ideal 
format for managing complex diseases in a primary care setting, 
with some SMAs also being conducted in hospitals (10, 11).
As with any new model of care, introducing SMAs into 
routine clinical care may encounter challenges and may have 
unanticipated negative effects. For instance, SMAs may introduce 
concerns around patient confidentiality or preference to visit their 
regular physician, as well as issues around the logistics of setting 
up SMAs, including availability of suitable spaces and materials 
and availability of trained staff with specific item number reim-
bursements (9, 12). It is also unknown whether SMAs may be 
more costly to the health-care system or whether they could have 
adverse effects on clinical outcomes or patient and/or physician 
satisfaction. Most importantly, the potential value of SMAs over 
any other form of clinical interaction in patients with T2DM has 
not been established and is a key first step toward their successful 
integration into routine diabetes care.
This review synthesizes current and emerging evidence on 
the effectiveness of SMAs in the management of T2DM and 
identifies relevant knowledge gaps. Specifically, we aimed to 
establish whether SMAs improved clinical outcomes compared 
to usual care, their acceptability among patients and providers, 
and whether they were associated with reduced costs or improved 
diabetes-related behavioral and lifestyle changes.
MATeRiALS AND MeTHODS
Major electronic databases including PubMed and Google 
Scholar were searched to identify studies of SMAs in patients 
with T2DM. The following keywords and phrases were used in 
various combinations: SMA, group medical appointments, group 
care, group visits, group-based education, T2DM. All publica-
tions from inception up to the when the search was conducted 
(February 2017) were considered. All articles identified within 
the initial search were screened for relevance and content by two 
independent reviewers (Kirthi Menon and Aya Mousa), and their 
bibliographies were searched for any additional relevant articles.
Criteria for inclusion were articles reporting observational 
studies or randomized or quasi-randomized trials where SMAs 
were delivered in any frequency and for any duration to patients 
with T2DM. Studies of SMAs in patients with type 1 diabetes or 
mixed or unspecified populations were excluded, as well as studies 
where SMAs did not involve a physician since these do not meet 
the classical definition of a SMA. The review covers retrospective, 
prospective, and randomized controlled studies in a narrative 
review format, and is not intended as a systematic review.
ReTROSPeCTive STUDieS
Study and Sample Characteristics
Three retrospective studies (10, 13, 14) were identified examining 
the effectiveness of SMAs on T2DM-related outcomes. Details of 
these studies are outlined in Table 1 (A). All three studies were 
conducted in the US and utilized medical records to compare 
patients who attended SMAs to a control group of patients 
who received usual care. One study by Culhane-Pera et al. (14) 
included three groups: an SMA group (n = 39), a control group 
derived from medical records (n = 216), and an additional com-
parison group of patients who declined participation in the SMAs 
(n = 22). There were no differences in demographic or clinical 
characteristics between SMA participants and those who declined 
participation in this study. Total sample sizes ranged from 160 
(13) to 988 (10) participants, and total numbers of participants 
attending SMAs over the study duration ranged from 39 (14) 
to 371 (10) participants. Medical record data were extracted for 
periods of 12 (13) and 13 months (14) and 3 years (10). However, 
the 3-year study by Harris et al. (10) did not report the numbers, 
TABLe 1 | Characteristics of studies in a review of physician-based SMAs in patients with type 2 diabetes.
Reference, 
country
Study design and setting Study duration (months); SMAs 
attended (n); frequency (n); duration 
(min); patients per SMA session (n)
Comparator n Mean age (years); sex, 
%; ethnicity (%)
Mean BMi (kg/m2); 
T2DM duration (years); 
Smokers (n)
Clinical 
outcomes 
measured
Main findings 
for effect of 
SMAs
(A) Retrospective studies
Harris et al., 
USA (10)
Retrospective (abstracted 
medical records); large 
midwestern veterans 
administration hospital
36 months (3 years);
NR (minimum 2 years of attending 
SMAs);
Duration NR;
n per SMA NR
Usual care 
(medical records)
n = 988
I: 371
C: 617
Age: 70.1
Male: 98%
Ethnicity: White (72); Black 
(20)
BMI: NR (53.9% obese)
Duration: NR
Current smoker: 413
HbA1c, SBP, 
LDL
NS
Culhane-Pera 
et al., USA 
(14)
Retrospective (diabetes registry 
medical records) with controls; 
federally qualified community 
health center
13 months;
7 SMAs (monthly for 3 months then 
quarterly);
210 min;
n = 10–16; median 7 per SMA
C1 = usual care; 
C2 = refused to 
participate (both 
medical records)
n = 277
I: 39
C1: 238
C2: 22
Age: 56.8
Male: 36%
Ethnicity: Hmong 
(originating in Southern 
China)
BMI: 28.5
Duration: 6.6
Smoker: NR
BMI, HbA1c, 
SBP, DBP, 
LDL, HDL, 
TC, TRIG, 
microalbumin/
creatinine ratio
HbA1c: NS;
Other outcomes 
only assessed 
for within group 
difference: NS
Bray et al., 
USA (13)
Retrospective (database 
medical records) with controls; 
Rural fee-for-service primary 
care practices
12 months;
4 SMAs over 6 months;
120 min;
n = 3–12 per SMA
Usual care 
(medical records)
n = 160
I: 112
C: 48
Age: 59.4
Male: 44.4%
Ethnicity: >90% Black
BMI: NR
Duration: NR
Smoker: NR
Weight, 
HbA1c, BP
↓HbA1c
(B) Prospective studies
Boegner et al., 
France (15)
Prospective pre-test/post-
test design; multidisciplinary 
private practice settings (GPs, 
specialists, etc.)
6 months;
2 SMAs (frequency NR);
Half-day;
Mean n = 4 per SMA
No control group/
comparator
n = 427
I: 322
C: N/A
Age: 64.6 ± 10.0
Male: 55.3%
Ethnicity: NR
BMI: 28.9
Duration: 11.5 ± 12.2
Current smoker: 26
Weight; 
HbA1c; FBG; 
SBP; DBP
↓HbA1c; ↓FBG
Dickman et al., 
USA (16)
Prospective pre-test/post-test 
design; Free primary care clinic
4 months;
4 SMAs (monthly)—80% of patients 
attended 4 SMAs;
90 min;
n = 8–12 per SMA
No control group/
comparator
n = 37
I: 30
C: N/A
Age: 57.0 ± 10.2
Male: 34%
Ethnicity: Hispanic (61); 
Asian (11); Middle Eastern 
(11); Black (8.5); White (8.5)
BMI: NR
Duration: NR
Smoker: NR
Weight, 
HbA1c, SBP, 
LDL
SBP: NS
Remaining 
outcomes: NR
Guthrie and 
Bogue, USA 
(17)
Prospective pre-test/post-test 
design; Community family 
medicine residency practice
2 months;
16 SMAs offered (NR attended—
patients advised to attend as many as 
possible);
60–90 min
n per SMA NR
No control group/
comparator
n = 48
I: 46
C: N/A
Age: 64.8;
Male: 39%;
Ethnicity: White (67); Black 
(24);
Hispanic (4); Asian/Pacific 
Islander (4); 
BMI: 34.5
Duration: NR
Smoker: NR
Weight, TC, 
LDL, HDL, 
TRIG, HDL/TC 
ratio
↓Weight
Palaniappan 
et al. USA (11)
Prospective with a created 
(matched) control group; 
Primary care clinic at research 
institute-affiliated hospital
24 months;
Mean of 3 SMAs attended over 
4–5 months (offered biweekly); median 
of 6 weeks between visits;
90 min;
n = 6–12 per SMA
Matched controls 
receiving usual 
office visit with 
same physician
n = 430
I: 74
C: 356
Age: 49.7;
Male: 34%;
Ethnicity: NR
BMI: 32.4;
Duration: NR;
Smoker: NR
Weight, BMI ↓Weight; ↓BMI 
between groups 
and associated 
with total SMAs 
attended
Pieber et al., 
Austria (18)
Prospective with concurrent 
non-randomized controls; Rural 
primary care clinics
6 months;
4 SMAs (weekly);
90–120 min;
n = 4–8 per SMA
Usual care 
(medical records 
from other GPs 
prior to initiating 
SMAs)
n = 94
I: 45
C: 49
Age: 64.7
Male: 45%
Ethnicity: NR
BMI: 30.2;
Duration: 7.3;
Smoker: NR
Weight, BMI, 
HbA1c; SBP, 
DBP, TC, TRIG
↓Weight; ↓BMI; 
↓HbA1c; ↓DBP; 
↓TRIG;
TC and SBP: NS
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Reference, 
country
Study design and setting Study duration (months); SMAs 
attended (n); frequency (n); duration 
(min); patients per SMA session (n)
Comparator n Mean age (years); sex, 
%; ethnicity (%)
Mean BMi (kg/m2); 
T2DM duration (years); 
Smokers (n)
Clinical 
outcomes 
measured
Main findings 
for effect of 
SMAs
Kirsh et al., 
USA (8)
Prospective with concurrent 
non-randomized controls; 
Primary care clinic tertiary 
academic medical center—
Veteran Affairs health system
4 months;
Drop-ins: 1–7 SMAS over 4 months 
(39% attended 1 SMA; 77% attended 
1–3 SMAs);
60–120 min;
n = up to 8 per SMA
Usual care 
(medical records 
from other GPs 
prior to initiating 
SMAs)
n = 79
I: 44
C: 35
Age: 60.6
Male: 97.7%
Ethnicity: NR
BMI: NR
Duration: NR
Smoker: NR
HbA1c, LDL, 
SBP
↓HbA1c; ↓SBP
(C) RCTs
Clancy et al., 
USA (22)
RCT; primary care university 
affiliated clinic
6 months;
6 SMAs (monthly);
120 min;
n = 19–20 per SMA
Usual care  
(details NR)
n = 120
I: 59
C: 61
Age: 54;
Male: 22%;
Ethnicity: Black (77.5)
BMI: NR;
Duration: NR;
Smoker: NR
HbA1c, TC, 
HDL, LDL
NS
Clancy et al., 
USA (27, 28)
RCT; Primary care university 
affiliated clinic
12 months;
12 SMAs (monthly)
120 min;
n = 14–17 per SMA
Usual care  
(details NR)
n = 186
I: 96
C: 90
Age: 56;
Male: 28%;
Ethnicity: Black (83.3)
BMI: NR;
Duration: NR;
Current Smoker:
I: 20; C: 19
HbA1c, TC, 
LDL, HDL, 
TRIG
NS
Gutierrez 
et al., USA 
(23)
RCT; Primary care university 
affiliated clinic
17 months;
36 SMAs offered (biweekly), actual 
SMAs attended NR;
Duration NR;
Mean n = 9 per SMA
Usual care  
(details NR)
n = 103
I: 50
C: 53
Age: NR;
Male: NR;
Ethnicity: Hispanic (100)
BMI: NR;
Duration: NR;
Smoker: NR
HbA1c ↓HbA1c
Trento et al., 
Italy (2- year 
follow up) (25)
RCT; Diabetes university 
affiliated clinic
24 months;
7–8 offered (quarterly);
120 min;
n = 9–10 per SMA
Usual care (7–8 
attended quarterly 
with individual 
education 
sessions)
n = 112
I: 56
C: 56
Age: 61.5;
Male: 54%;
Ethnicity: NR
BMI:
I: 29.7 ± 4.5;
C: 27.8 ± 4.1;
Median (range) duration:
I: 9.4 (1–23);
C: 9.8 (1–39);
Current Smoker:
I: 10; C: 15
Weight, BMI, 
HbA1c, 
FBG, TC, 
HDL, TRIG, 
creatinine, 
albuminuria
↓HbA1c, ↑HDL,
Trend for ↓BMI 
and ↓TRIG in 
SMA group.
Trento et al., 
2004, Italy 
(5-year follow 
up) (20)
60 months (5 years);
19 SMAs offered (quarterly);
120 min;
n = 9–10 per SMA
n = 84
I: 42
C: 42
↓Weight; 
↓HbA1c
Trend for ↓BMI in 
SMA group.
Trento et al., 
Italy (21)
RCT; diabetes university 
affiliated clinic
48 months (4 years)
14 SMAs (quarterly);
60 min;
n = 9–10 per SMA
Usual care (14 
attended quarterly)
n = 581
I: 315
C: 266
Age: 69.3 ± 8.4;
Male: 51%;
Ethnicity: NR
BMI:
I: 30.6 ± 4.9;
C: 29.3 ± 5.1;
Median duration:
I: 15.7 ± 6.9;
C: 16.6 ± 7.2;
Current Smoker:
I: 79; C: 67
Weight, BMI, 
HbA1c, FBG, 
TC, HDL, LDL, 
TRIG, SBP, 
DBP, creatinine
↓Weight, ↓BMI, 
↓FBG, ↓HbA1c, 
↓TC, ↓LDL, 
↓TRIG, ↓SBP, 
↓DBP, and ↑HDL
Rygg et al., 
Norway (24)
Open pragmatic RCT 12 months;
3 SMAs (biweekly for 6 weeks or 
triweekly for 9 weeks)
300 min;
median n = 4
Usual care  
(details NR)
n = 146
I: 73
C: 73
Age: 66;
Male: 53%;
Ethnicity: Norwegian- 
White (100)
BMI:
I: 30.0 ± 4.3;
C: 30.7 ± 5.5;
Median (IQR) duration:
All: 5 (2.5–10);
Smoker: NR
Weight, BMI, 
HbA1c, TC, 
HDL, TRIG, 
SBP, DBP, 
Creatinine
NS
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frequencies, or duration of SMAs attended, specifying only that 
patients were included if they attended at least one SMA annually 
for two consecutive years. In the two remaining studies, patients 
attended four 120-min SMA sessions over 6 months (13) or seven 
210-min SMAs over 13 months (14). The number of participants 
was 3–12 (13) and 10–16 (14) per SMA session (Table  1, A). 
Interventions delivered as part of the SMAs included a group 
education component in two studies (13, 14), while the third 
did not specify (10). All three studies were targeted at specific 
population groups which included: an older Veteran population 
(10); a rural minority group of primarily African-Americans 
(13); and a group of refugees from the Vietnam War known as 
Hmong people (originating from Southern China) (14). The 
study by Bray et al. (13) specifically recruited high-risk patients 
with HbA1c >7%, blood pressure >135/85 mmHg, or physical 
or laboratory evidence of end-organ complications, including 
retinopathy, neuropathy, or nephropathy.
Clinical Outcomes
Clinical outcomes reported included anthropometry (weight 
and/or BMI; n  =  2), glycated hemoglobin (HbA1c; n  =  3), 
blood pressure (n =  3), and serum lipids (n =  2), including 
total cholesterol, high- and low-density lipoprotein cholesterol 
(HDL; LDL), and triglycerides. Culhane-Pera et  al. (14) also 
measured microalbumin/creatinine ratio. In the two studies 
reporting anthropometric outcomes (13, 14), weight and BMI 
did not differ significantly between patients who attended four 
to seven SMAs over 6–13 months and those who received usual 
care. Similarly, no differences were observed in blood pressure, 
LDL, or microalbumin/creatinine ratio between SMA and usual 
care patients in any of the studies (10, 13, 14). Only the study in 
African-Americans (13) reported improvements in HbA1c, from 
8.2 to 7.1% in those who attended four SMAs over 6 months ver-
sus usual care (8.3–8.6%). Note that this was the only study which 
specifically recruited high-risk patients with HbA1c > 7%, and 
the SMA was comparatively intensive with 2-h SMAs attended 
four times over 6 months (13). Thus, it is possible that SMAs may 
be more effective when delivered frequently to patients with poor 
glycemic control. The lack of differences reported between SMA 
and control groups for most clinical outcomes may be due to the 
retrospective nature of these studies, since they were not designed 
specifically for these outcomes. Alternatively, it is possible that 
SMAs were not superior to standard care in improving clinical 
outcomes in these studies, or that they may only be effective in 
certain subgroups of patients; however, drawing conclusions 
regarding specific subgroups is limited by the diverse demo-
graphic, socioeconomic, and cultural characteristics of the study 
populations.
Other Outcomes
Harris et  al. (10) examined health-care utilization and found 
no differences in emergency department (ED) visits; however, 
the mean total health-care visits at study-end was 28 in SMA 
participants compared to 19 in patients receiving usual care (10). 
This was likely because this study had a high-risk SMA cohort 
who had a higher proportion of smoking, alcoholism, substance 
abuse, depression, etc., as well as higher ED and total health-care TA
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visits at baseline, compared to the usual care group. None of these 
baseline differences were adjusted for in the analyses, thus results 
should be interpreted with caution.
Culhane-Pera et  al. (14) investigated changes in behavioral 
outcomes (24-h diet and exercise recall), and mental health 
outcomes (depression and anxiety scores on Hmong Likert 
scale survey) pre- and post-SMAs. These were not compared 
between groups due to unavailable control group data. After 
seven SMAs over 13 months, total anxiety-depression scores as 
well as anxiety-subscale scores were improved, with no change in 
depression-subscale scores (14). There were no changes observed 
in dietary or exercise habits in SMA participants. These analyses 
involved only 39 low-income, elderly Hmong refugees, hence 
interpretation of these findings is limited. The lack of changes 
observed in diet and exercise habits in this study may also be 
due to difficulties associated with lifestyle changes, which often 
require regular contact and monitoring, and thus may depend 
more on the frequency of contact rather than on the model of care 
delivered. Overall, conclusions on SMA effectiveness are difficult 
to draw from this group of studies.
PROSPeCTive STUDieS
Study and Sample Characteristics
Six prospective studies (8, 11, 15–18) of SMAs in T2DM were 
identified and are detailed in Table  1 (B). All studies were 
conducted in the US (n = 4) or Europe (France, n = 1; Austria, 
n = 1) (Table 1, B). Three of the six studies were of a pretest/
posttest design while the remaining three compared SMAs with 
a control group created by using data from medical records of 
patients attending usual care. Sample sizes varied considerably 
with total numbers of participants ranging from 37 (n =  30 
analyzed) (16) to 430 participants (11). However, in studies 
which had both an SMA group and a control group (n =  3) 
(8, 11, 18), the largest number of participants in the SMA group 
was 74 (11). Study durations and numbers of SMAs attended were 
limited, with most studies having between two and four SMAs 
over 4–6 months. One study by Guthrie and Bogue (17) offered 
16 SMAs over 2 months but did not report the number of SMAs 
attended, while Kirsh et  al. offered drop-ins (8) and reported 
that 77% of participants attended one to three SMA sessions over 
4 months. All studies reported SMA sessions of between 60 and 
120 min, with the exception of one study (15) which conducted 
half-day long SMAs. The number of participants in each SMA 
ranged between 4 (15) and 8–12 (16) per session, and one study 
(17) did not report the number of participants per session.
The types of interventions delivered within the SMAs varied 
across studies; however, all included an educational component 
(15–18) or discussion of relevant health-related topics and 
concerns (8, 11), in addition to the individual patient or medi-
cation reviews (8, 16, 18). In the three studies which included 
a control group, two formed the control group using medical 
records of patients attending GPs who had not yet commenced 
SMA sessions within their practices (8, 18). The third study 
used medical records of patients attending individual visits with 
the same physician who performed the SMAs, where patients 
were included as controls if they had a similar age, sex, BMI, 
and weight as patients in the SMA group (11). Some studies 
targeted specific population groups including Veterans at high 
risk of cardiovascular disease (CVD) (HbA1c >  9%; systolic 
blood pressure (SBP) >160  mmHg; and LDL >130  mg/dL) 
(8) or low-income, uninsured, and/or unemployed groups 
(16, 18) (Table 1, B). Participant HbA1c level was as an inclu-
sion criterion in the study of Veterans at high-risk of CVD (8) as 
noted above (HbA1c > 9%), while another study (16) specified 
a HbA1c < 9% in their inclusion criteria.
Clinical Outcomes
Clinical outcomes included weight and/or BMI, fasting blood 
glucose (FBG), HbA1c, blood pressure, and serum lipids 
(Table 1, B). Five studies (11, 15–18) measured weight and/or 
BMI as an outcome, three of which reported significant findings. 
Palaniappan et al. (11) and Pieber et al. (18) reported reduced 
weight (−0.5 and −2.7  kg, respectively) and BMI (−0.3 and 
−1.1 kg/m2, respectively) in those who attended three to four 
SMAs over 4–6 months, compared to no change in controls. The 
third study by Guthrie and Bogue (17) was a pretest posttest 
design which reported a weight loss of −4.1 kg within the SMA 
group, who were offered up to 16 SMAs in 2 months. The studies 
which found no difference in weight or BMI were in non-obese 
participants (15), had a small sample size (n = 30) (16), or had 
infrequent SMAs with a limited duration to observe beneficial 
effects on weight (two SMAs in 6 months) (15). Because weight-
loss strategies often require close supervision and monitoring, 
these findings suggest that longer durations and more frequent 
SMAs could be beneficial in promoting weight loss in these 
patients. This is supported by one study (11) which reported 
that weight loss and BMI reduction were directly correlated 
with the total number of SMAs attended. Importantly, the 
studies by Palaniappan et  al. (11) and Pieber et  al. (18), both 
of which reported improved weight loss in the SMA group 
versus controls, did not specify the number of visits attended by 
the control groups. Thus, it is possible that SMA attenders were 
compared to both attenders and non-attenders in usual care, 
making it difficult to ascertain whether the beneficial effects on 
weight loss are attributed to the SMA model of care or simply to 
the increased attendance and monitoring of patients in the SMA 
groups. Larger studies are needed to establish the effectiveness 
of SMAs in improving anthropometric outcomes, with sufficient 
detail of the number and nature of usual care visits attended by 
the control groups.
Regarding glycemic outcomes, one study measured both FBG 
and HbA1c and four measured HbA1c only. In a pre-test post-test 
study by Boegner et al. (15), FBG reduced from 8.1 to 7.9 mmol/L 
and HbA1c reduced from 7.6 to 7.4% after 6 months in patients 
who received two half-day SMA sessions. However, there was no 
control group in this study and although improvements in glyce-
mic control were small, these may have resulted from intensified 
treatment since many of the SMA patients switched from oral 
agents to insulin during the study period. In the remaining three 
studies which examined HbA1c in Veterans at high risk of CVD or 
in low-income uninsured groups (8, 16, 18), two reported signifi-
cantly lower HbA1c (−1.4 and −0.5%) in those who attended one 
to seven SMAs over 4–6 months compared with controls (−0.3 
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and +0.3%, respectively) (8, 18). The third study in a low-income 
cohort (16) found no difference in HbA1c pre- and post- SMA in 
patients attending monthly SMAs for 4 months. It is possible that 
SMAs were not beneficial for improving HbA1c in this cohort; 
however this study had no control group and included only 30 
participants, hence the null findings should be interpreted in light 
of the limitations of this study and the potential lack of statistical 
power.
Blood pressure was measured in four studies with inconsist-
ent results. Kirsh et al. (8) reported lower SBP (−14.8 mmHg) in 
their high-risk Veteran cohort after receiving one to seven SMAs 
over 4 months compared to controls (−2.5 mmHg), while Pieber 
et  al. (18) reported that in their low-income cohort, attending 
four SMAs over 6 months reduced diastolic blood pressure (DBP) 
by −11.1 mmHg compared to −5.4 mmHg in controls, with no 
change in SBP. The remaining two studies (15, 16) found no dif-
ference between pre- and post- SBP or DBP in patients receiving 
two to four SMAs over 4–6 months. However, the latter two stud-
ies had no control group, and one had a small sample size (16), 
while the other held only two SMA sessions over 6 months (15), 
which may explain their lack of findings.
Four studies (8, 16–18) measured serum lipids includ-
ing total cholesterol (n =  2), HDL (n =  1), LDL (n =  3), and 
triglycerides (n =  2). Only the study by Pieber et  al. (18) in a 
low-income cohort reported a significant decrease in triglycer-
ides (−0.6  mmol/L) in patients who attended four SMAs over 
6 months, compared to increased triglycerides in those receiving 
usual care (+0.2 mmol/L). This was the largest (n = 94 compared 
to n < 74) and longest (6 months compared to ≤4 months) study 
measuring lipids, suggesting that studies with larger sample sizes 
and sufficient follow up durations are needed to observe benefi-
cial effects of SMAs on serum lipids.
Other Outcomes
Most studies reported several other outcomes which included 
patient satisfaction, cost-effectiveness of SMAs, and whether 
SMAs improved adherence to treatment guidelines, diabetes-
related knowledge and self-management, and lifestyle habits such 
as diet and exercise. Patient satisfaction was reported in one study 
(16) which found that 95% of patients rated SMAs as excellent or 
very good and stated that they would participate in SMAs again. 
Only the study by Pieber et al. (18) assessed the potential cost-
savings associated with SMAs. Here, the number of patients who 
switched from oral hypoglycemic (OHG) medications to diet and 
exercise doubled from 16% to 29% in the SMA group, with no 
significant change in controls (18–14%). Moreover, daily OHG 
use in the SMA group reduced from 2.2 to 1.6 tablets per patient 
per day, compared to an increase in controls from 1.9 to 2.3 tablets 
(18). The reduction in OHG use was likely due to the significant 
weight loss and improved glycemic control experienced in the 
SMA group in this study (mean weight loss of −2.7 kg and change 
in HbA1c of −0.5% as reported earlier) (18). Nevertheless, as a 
result of reduced OHG prescriptions, it was estimated that SMAs 
reduced routine health care costs by UK £33 per patient per year 
compared to a UK£30 increased cost in usual care patients (18).
Adherence to specific performance targets (HbA1c <9%; SBP 
<160 mmHg; and LDL <130 mg/dL) was assessed in the study 
by Kirsh et al. (8) of Veterans at high-risk of CVD. The propor-
tion of patients meeting targets in the SMA group rose by 36, 
25, and 14% for HbA1c, SBP, and LDL, respectively, compared 
to no change for HbA1c and LDL and a decreased adherence to 
SBP targets (from 27 to 18%) in the control group (8). This may 
be because SMAs promote a team approach and engage patients 
in their own self-management, which may improve adherence to 
targets, particularly in high-risk groups (8).
Diabetes-related knowledge and self-management were assessed 
in two studies (15, 18). Using a validated 21-item ques tionnaire, 
Pieber et al. (18) found that total knowledge score for the SMA 
cohort increased by +25 points compared to +1 in controls, and 
92% of SMA patients reported self-monitoring compared to 82% 
of controls. Similarly, Boegner et al. (15) reported that diabetes 
knowledge and self-management improved from pre-SMA scores 
of 56 and 77% to 72 and 82%, respectively, after 6  months of 
attending SMAs.
Lifestyle and behavioral outcomes were assessed in two studies 
(16, 17), both of which had no control group. After 2–4 months of 
SMAs, self-reported exercise per week increased in both studies 
(16, 17), with Dickman et al. (16) reporting that exercise increased 
in conjunction with increased attendance to SMAs. Self-reported 
changes in diet such as reducing red meat consumption and 
increasing intake of plant-based foods were also improved after 
attending SMAs for 2 months (17). Similarly, Dickman et al. (16) 
found that 97% of patients attending SMAs for 4 months achieved 
or almost achieved their self-prescribed goals, which included 
reducing stress and unhealthy food consumption, increasing 
exercise, and taking prescribed medications.
Hence, while it is difficult to draw conclusions from these stud-
ies based on clinical outcomes, there do appear to be significant 
advantages in SMAs in patient satisfaction, adherence to targets, 
knowledge, and lifestyle and behavioral outcomes. These need to 
be examined in more depth in future evaluative studies.
RANDOMiZeD CONTROLLeD TRiALS
Study and Sample Characteristics
Ten articles were identified reporting eight randomized controlled 
trials (RCTs) of SMAs held exclusively in T2DM patients. Details 
of these RCTs are outlined in Table 1 (C). All studies were con-
ducted in the US and Europe, and with the exception of one three-
arm trial (19), all studies were parallel-design RCTs. Sample sizes 
varied substantially, ranging from 84 (20) to 581 (21) participants 
in total, with the largest intervention group comprising a total of 
315 participants who attended SMAs over four years (21). Study 
durations ranged from 6 months (22) to 5 years (20), with three 
of the eight RCTs being of >12 months duration. However, the 
numbers of SMAs attended in most studies was ≤8 SMAs over 6 
months to 2 years, and one study by Gutierrez et al. (23) offered 
36 SMAs over 17  months, but did not report the number of 
SMAs actually attended. The majority of RCTs conducted SMAs 
monthly with the most frequent being biweekly (23, 24), while 
the studies by Trento et al. (20, 21, 25) conducted SMAs every 3 
months (quarterly) and compared these with quarterly usual care 
visits. Most SMA durations ranged from 60 (21, 26) to 120 min 
(20, 22, 25, 27), with the longest single SMA session lasting 5 h 
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(24). In six of the eight RCTs, SMA sessions were relatively small, 
involving 4–10 patients, while the two studies by Clancy et al. (22, 
27) had 14–17 and 19–20 patients per SMA (Table 1, C).
Regarding the interventions provided within the SMAs, all 
studies involved group education sessions in addition to the 
individual patient consultations with the physician within the 
group setting. The control group consisted of usual care in the 
majority of studies, however two studies employed enhanced 
usual care. In the studies by Trento et al. (20, 21, 25), patients 
attending 7 to 14 quarterly SMAs were compared with a control 
group of patients also attending between 7 and 14 quarterly 
usual care consultations with individual education sessions over 
a 2- to 5-year period. Similarly, Naik et al. (26) compared those 
attending four SMAs over 3  months with a control group of 
patients who attended two usual care consultations, each with a 
120-min diabetes education session following the consultation. 
The remaining RCTs did not describe the number, frequency, or 
duration of usual care visits attended by the control groups. The 
three-arm study by Schillinger et  al. (19) compared the SMA 
intervention with a usual care group and with a group receiving 
automated telephone self-management support and nurse fol-
low up. Sample characteristics varied across the RCTs. African-
Americans made up >70% of the sample in the studies by Clancy 
et  al. (22, 27), while Gutierrez et  al. (23) and Rygg et  al. (24) 
included 100% Hispanics or White Norwegians, respectively. 
Naik et  al. (26) included older Veterans (aged 50–90  years) 
of which 31% were African-American, and Schillinger et  al. 
(19) included a diverse population of low-income/low-literacy 
Asians, African-Americans, White Latinos and White non-
Latinos, and others (Table 1, C). Over half the studies (19, 22, 
23, 26, 27) specified an elevated HbA1c (>7 to >8.5%) as an 
inclusion criteria, while the remaining had no specific HbA1c 
requirement (20, 21, 24, 25).
Clinical Outcomes
Clinical outcomes measured included weight, BMI, FBG, HbA1c, 
lipid profiles, blood pressure, serum creatinine, and albuminuria 
(Table  1, C). Three trials assessed both body weight and BMI 
(20, 21, 24, 25) and one examined BMI only (19). Only the RCTs 
by Trento et al. (20, 21, 25) found a difference in weight or BMI 
between SMA and control groups after 2, 4, and 5 years of quar-
terly SMAs. In these RCTs, no changes in weight were observed 
after two years; however, at four- and five- years follow up, change 
in body weight was −1.6 and −3.5 kg in the SMA group compared 
to −0.24 and +2.0 kg in the control group, respectively. Similarly, 
BMI reduced by −0.6  kg/m2 in the SMA group compared to 
+0.6 kg/m2 in the control group in the four-year trial (21), with 
trends for reduced BMI also observed in the 2-year (25) and 
5-year (20) trials. In contrast, Rygg et al. (24) found no differences 
in weight or BMI after biweekly or triweekly SMAs for 6–9 weeks 
and Schillinger et  al. (19) reported no change in BMI after 
monthly SMAs for 9 months. Discrepant findings may be due to 
the different sample sizes since the only RCT which reported a 
significant reduction in both weight and BMI in the SMA group 
was the largest trial with 581 participants (21). It also appears 
that studies with longer durations had more favorable effects on 
anthropometric outcomes. This is likely because a prolonged 
follow up would allow more time for patients to implement the 
weight-loss advice received through SMAs and for investigators 
to observe changes in these outcomes.
Fasting blood glucose was measured in the two RCTs by 
Trento et al. (20, 21, 25), one of which reported no differences 
between groups at 2-years (25) and 5-years (20) follow up, while 
the second (21) reported a significantly lower FBG level in the 
SMA group after four years of quarterly SMAs. Again, this is 
likely due to the larger sample size (n = 518) in the latter study 
and greater statistical power to observe effects. HbA1c was 
measured in all eight RCTs, four of which reported a reduced 
HbA1c after 12 months to 5 years of SMAs (20, 21, 23, 25, 26). 
One of these trials found that HbA1c remained stable in the 
SMA group (7.4% at baseline; 7.5% at 2 years; 7.3% at 5 years), 
but worsened in the control group, despite the control group 
receiving usual care plus individual education sessions (7.4 to 
8.3 to 9.0%, respectively) (20, 25). Similarly, in the second trial 
which was the large four-year RCT by Trento et al. (21), HbA1c 
at follow up was 1.5% lower in the SMA group compared to 
controls. The study by Gutierrez et al. (23) in a Hispanic popu-
lation reported a 1.2% reduction in HbA1c in the SMA group 
after 17  months, compared to a 0.7% reduction in controls, 
while the study in older Veterans by Naik et al. (26) found that 
HbA1c at 12 months follow up was 0.7% lower in the SMA group 
compared to the control group who received enhanced usual 
care with two diabetes education sessions. In the remaining 
four trials (19, 22, 24, 27), no significant differences in HbA1c 
were seen between SMA and control groups after 6–12 months. 
Disparate findings may be explained by the substantial hetero-
geneity in study design, including in patient characteristics, the 
durations and frequencies of SMAs, and lack of standardization 
of the interventions provided. Importantly, SMAs appeared to 
be less effective in studies which were <12 months in duration, 
or where the population included diverse ethnic groups or 
non-English speakers (19) or was limited to low-income and 
low-literacy populations (19, 27). Consistent with findings from 
the retrospective and prospective studies discussed above, this 
highlights the need for longer follow ups to observe benefits 
of SMAs, and suggests that perhaps cultural or socioeconomic 
factors may influence the extent by which SMAs can improve 
clinical outcomes.
Blood pressure was measured in three trials (19, 21, 24) 
but only the large four-year RCT by Trento et  al. (21) found a 
significant difference between SMA and control groups in both 
SBP (138.0 versus 143.6  mmHg, respectively) and DBP (79.1 
versus 80.6 mmHg, respectively). Lack of effects observed in the 
other two trials may be due to the shorter durations (≤12 months 
versus 4 years) and fewer number of SMAs attended (<5 versus 
14 SMAs).
Five of the eight studies measured serum lipids, including 
total cholesterol (5 RCTs), HDL (5 RCTs), LDL (3 RCTs), 
and triglycerides (4 RCTs). Of these, three trials (22, 24, 27) 
reported no differences in lipid profiles between those who 
attended 3–12 SMAs over 6–12 months compared to controls. 
Conversely, Trento et  al. (25) found that HDL increased by 
+0.2  mmol/L in patients who attended seven to eight SMAs 
quarterly for two years compared to those attending usual care 
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plus individual educational sessions; however there were no 
differences in total or HDL cholesterol or triglycerides at the 
5-year follow up of the same patients (20). In the larger study 
by Trento et al. (21) (n = 518), patients who attended a total of 
14 SMAs quarterly over four years had increased HDL at follow 
up compared to controls (+0.1 versus −0.01 mmol/L), as well 
as reduced total cholesterol (−0.7 versus +0.1 mmol/L), LDL 
(−0.6 versus −0.01  mmol/L), and triglycerides (−0.4 versus 
+0.1  mmol/L). Differences in sample sizes, study durations, 
and frequency of SMAs may, in part, explain the disparate find-
ings. Similar to findings from observational studies, it appears 
that improvements in some or all serum lipids in these RCTs 
were more frequently reported in larger studies, with more 
frequent SMAs (7–14 SMAs) attended over longer durations 
(>12 months) (21, 25).
Other clinical outcomes measured included creatinine (4 RCTs) 
and albuminuria (1 RCT). Again, only the large four-year trial 
by Trento et  al. (21), found a significant increase in creatinine 
in the control group (+8.8 mmol/L) with no change in the SMA 
group (+0.9 mmol/L). There were no differences in albuminuria 
between groups at two or 5  years follow up in the single RCT 
which measured this outcome (20, 25). Further studies are needed 
to confirm whether attending SMAs can improve these outcomes 
compared to usual care.
Other Outcomes
Other outcomes measured in these studies included cost- 
effectiveness of SMAs, adherence to American Diabetes 
Association (ADA) guidelines, quality of life (QoL), diabetes 
knowledge scores, and diabetes self-efficacy. Two studies by 
Clancy et al. (22, 28) compared the costs of SMAs to usual care 
[cost-analysis for 2003 study (22) reported in a separate article 
(29)]. The 2003 study (22, 29) found significantly higher total 
costs (inpatient, outpatient, and ED costs) for SMAs compared 
with usual care (USD $2,886 versus $1,490 per patient over 
6 months). These increased costs may have resulted from ‘patient 
activation’, whereby SMAs alerted patients to the importance of 
certain aspects of care and increased their service-utilization 
to ‘catch up’ to care which had previously been neglected (29). 
It is also likely that the six month study duration provided insuf-
ficient time to observe benefits of SMAs in improving self-care 
and reducing costs in the long term. This is supported by the later 
study by Clancy et al. (28), where the same costs after one year 
were significantly lower in the SMA group (USD $5,869 versus 
$8,412 per patient) compared to controls. Similarly, the Trento 
et al. study which reported outcomes at two (25) and 5 years (20) 
follow up also published a separate cost-analysis (30) at 4-year 
follow-up in the same patients. Here, although the SMA group 
had slightly higher direct and indirect costs; authors concluded 
that SMAs were cost-effective as only USD $2.12 was required 
for an extra point gained on the QoL score (30). Overall, costs 
are an important consideration when evaluating the feasibility 
of SMAs, and further studies elucidating the cost-effectiveness 
of SMAs are warranted.
In the two studies (14, 28) which measured adherence to ADA 
guidelines, both reported an increased adherence to the recom-
mended standards of care after monthly SMAs for 6–12 months 
compared to controls. While SMAs may be beneficial for promot-
ing adherence, further studies are needed to confirm this.
Four RCTs (20, 21, 23–25) measured QoL and diabetes-related 
knowledge. All but one (24) reported improved QoL scores in 
SMA groups compared to controls, following attendance to >7–8 
SMAs for 1.5–5 years. In the one study which found no difference 
in QoL between groups (24), patients attended only three SMAs 
over a 6- to 9-week period, which may have been an insufficient 
number of SMAs and/or inadequate time to observe changes 
in QoL in these patients. Nevertheless, all four studies (20, 21, 
23–25) reported improved diabetes knowledge in the SMA group 
at study-end, compared to controls, likely due to the educational 
component included in SMAs.
Regarding diabetes self-efficacy (a tool which evaluates a 
person’s ability to perform certain diabetes-related management 
tasks), this was measured in two RCTs (19, 26), both of which 
found no improvement in those who attended four SMAs over 
9–12 months compared to controls. These studies were restricted 
to older Veterans (26) or low-income low-literacy groups (19), 
which limits the generalizability of their findings. Additional 
psychosocial and behavioral outcomes were assessed including 
health behaviors, problem areas in diabetes, diabetes treatment 
satisfaction, problem-solving ability, trust in physician, and 
patient care assessments. Outcomes for these measures were 
highly variable across the studies, primarily due to the lack of 
standardization and use of different tools and scoring methods, as 
well as the different types of SMA interventions delivered, where 
some included goal setting, interactive learning, and problem-
solving activities, while others did not. Importantly, many vari-
ables were reported only in individual studies, thus limiting the 
ability to compare findings across studies.
In summary, it appears that clinical outcomes from RCTs are 
mixed, as with the previous studies reviewed. Cost comparisons 
are also unclear, although cost-effectiveness may be more in favor 
of SMAs and further good-quality studies are required to clarify 
this. Behavioral factors such as adherence, QoL, and knowledge 
appear to be benefits of SMAs; however there is less convincing 
evidence for other behavioral change.
SUMMARY AND LiMiTATiONS  
OF THe LiTeRATURe
Overall, studies examining the effectiveness of SMAs in improv-
ing clinical outcomes for T2DM patients have produced incon-
sistent results. Approximately half the studies found beneficial 
effects on anthropometric and metabolic outcomes (5 of 9 for 
weight and/or BMI; 2 of 3 for FBG; and 8 of 14 for HbA1c), while 
a lesser number of studies reported significant effects on blood 
pressure and lipids (3 of 11 for both). It was apparent however, 
that studies with larger sample sizes and regular/frequent SMA 
visits over longer follow up periods (>12  months), were more 
likely to report beneficial effects on clinical outcomes, and this 
was consistent across the different study designs.
Our findings align with recent meta-analyses (31–33) of 
observational studies and randomized and non-randomized 
trials which examined group visits in cohorts of patients with 
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type 1 or type 2 diabetes, or a mix of both (32). All three meta-
analyses reported improved HbA1c (31–33), and one also 
reported improved SBP in group visits compared to usual care 
(31), while another reported that weight, FBG, DBP, and some 
lipids improved, however this was inconsistent across different 
time-points (33). In subgroup analyses, Odgers-Jewell et al. (33) 
reported a greater effect on HbA1c in studies with smaller numbers 
of patients per group session and greater contact time; however 
significant heterogeneity was observed. In meta-regression by 
Housden et al. (32), patients who attended group visits for longer 
periods had better HbA1c outcomes, with a 0.25% reduction for 
every year of participation. The frequency of group visits did not 
fully explain the difference in effect size, indicating that duration 
of treatment had a greater effect on HbA1c than the number of 
visits attended per year (32). However, these meta-analyses differ 
from the present review in that they all included studies where 
the group visit teams did not necessarily include a physician, 
and hence these visits did not meet the classical definition of a 
SMA (31, 32). To date, no systematic reviews or meta-analyses 
have examined the effectiveness of SMAs (which by definition 
must include a physician) in the management of T2DM. Here, 
we address this knowledge gap by reviewing studies of physician 
based SMAs, where we found that more regular/frequent SMA 
visits over longer durations appeared to be more beneficial for 
improving clinical outcomes compared to usual care in T2DM 
patients.
Our review also highlights key limitations and substantial 
heterogeneity in the literature, particularly for non-clinical 
outcomes including cost-effectiveness, adherence to guidelines, 
diabetes knowledge and self-management, and health behaviors. 
For instance, some studies (10, 29) reported increased costs asso-
ciated with greater health-care utilization (total, ED, inpatient, 
or outpatient visits), while others reported reduced costs (28), 
particularly when improved QoL scores were factored in (30), or 
when decreased medication was used as a proxy for estimating 
health-care costs (18). Lack of consistency in the methods used 
to determine cost reductions associated with SMAs hinders our 
ability to draw valid conclusions regarding their cost-effectiveness 
in comparison to usual care. To further complicate the matter, 
what constitutes usual care and the number and frequency of 
visits in the usual care control groups was defined inconsistently 
or not at all in many of the studies, which is a key factor needed to 
make accurate comparisons regarding whether the SMA model is 
superior to standard care.
For other outcomes, such as adherence to guidelines, QoL, and 
diabetes knowledge, most studies reported that SMAs were more 
effective in improving these outcomes compared to usual care. 
However, interpretation of these findings is limited by several 
factors. First, whether these improvements translated into bet-
ter self-management and improved clinical outcomes was not 
captured in the current literature. Given that none of the studies 
examined maintenance of effects after the intervention ended, 
it remains unclear whether clinical or behavioral outcomes of 
SMAs are sustainable in the long term.
Second, the complex and multi-faceted interventions delivered 
and different tools used to measure these outcomes make it dif-
ficult to compare findings across studies. Consequently, it was not 
possible to ascertain which, if any, interventions within the SMAs 
(e.g., improved peer support or improved self-management) were 
most effective and for whom. Most studies also did not describe 
the components of the intervention in sufficient detail for repli-
cation, particularly the content of the group education sessions. 
Comparisons of SMA interventions versus enhanced usual care, 
which include individual or group educational sessions, also war-
rant further investigation.
Third, many studies tended to focus on very narrow popu-
lation groups, such as Veterans, refugees, rural or minority 
ethnic groups, or low-income low-literacy populations. While 
targeting these high-need and high-risk groups is important, it 
makes it difficult to generalize results on a broader population-
scale. Large-scale studies would help to clarify the practicality 
of SMAs on a population level and may also identify subgroups 
of patients which would benefit more or less from SMAs. 
Whether SMAs may be effective in engaging those patients who 
would not otherwise engage with usual care also remains to be 
established.
Moreover, limited data were reported on patient or provider 
satisfaction, and these elements are critical for successful imple-
mentation of SMAs. As yet, it remains unclear whether certain 
groups would be more accepting of SMAs than others. It is 
hypothesized that certain individuals, such as independent or 
self-motivated patients may find the disclosure of illness and the 
group nature of SMAs stressful (34). Certain cultural groups, 
particularly those in tight-knit communities, may require greater 
anonymity in the clinical encounter to prevent community-based 
stigma, and hence may be opposed to the SMA model (34). This 
may further vary according to SMA type, thus additional studies 
are needed to clarify what works and for whom.
Finally, most studies were not conducted in “real world” settings, 
with most taking place in academic, government, or vertically 
integrated systems such as Veteran Administrations, all of which 
tend to have very high quality of care (31). These settings were 
likely chosen because chronic care redesign interventions are 
difficult to implement in independent fee-for-service clinics, pri-
marily due to lack of research interest or lack of financial benefits 
(31). Although it is unclear whether the settings used in these 
studies influenced their results, caution should be taken when 
considering using these findings to guide SMA implementation 
outside such systems.
Overall, our review highlights that there are far more gaps 
in the literature than there are definitive results regarding the 
benefits of SMAs in the management of T2DM. Currently, the 
elements of SMAs that are important for potency, effectiveness, 
or generalizability, or which are critical in predicting improved 
outcomes, remain unknown. The nature and variations of the 
SMA process are likely to always create some confusion and 
difficulties in interpreting the evidence. While more structured 
studies may decrease this confusion, there is an immediate need 
for more Proof of Concept work to show the potential value of 
such an approach in clinical practice, as well as to provide direc-
tion for the most appropriate ways in which these may be offered. 
Without further studies which elucidate the most effective SMA 
interventions and the populations which would benefit most, 
implementation of these SMAs for the management of T2DM will 
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be based more on reasoned judgment than on evidence-based 
decision making.
CONCLUSiON AND FUTURe DiReCTiONS
Type 2 diabetes mellitus is a complex chronic disease often 
accompanied by complications and comorbidities (1). Managing 
T2DM via an integrated model of care such as SMAs may provide 
a practical solution for relieving the increasing time and cost 
pressures for both physicians and the broader health system. 
Designed to meet the clinical, educational, and psychosocial 
needs of patients, SMAs may be more effective and more popular 
among both patients and providers than usual care in engaging 
patients and promoting education and self-care, with potential 
long-term cost and health benefits.
Our review suggests that SMAs may improve intermediate 
clinical outcomes for T2DM, such as HbA1c, as well as some 
behavioral outcomes such as diabetes knowledge and adherence 
to guidelines, but only when SMAs are attended regularly over 
longer periods of time. While it is expected that any model of 
care delivered regularly over time would likely improve clinical 
outcomes, SMAs have the potential to achieve this while sav-
ing costs and relieving some of the current time and resource 
demands on physicians and the wider health-care system. 
However, the effectiveness of SMAs in this regard is yet to be 
established. Collectively, our findings suggest the need for a 
modified form of SMAs which offers a structured educational 
program together with the benefits of a medical consultation, 
more appropriately called a “Programmed Shared Medical 
Appointment” (PSMA). We are currently testing Proof of 
Concept of PSMAs for weight control in Australia in a project 
due to be completed in 2018.
In the meantime, definitive conclusions cannot be drawn 
regarding the most appropriate patients or settings for a diabetes 
SMA, nor on the SMA components which may be particularly 
successful. Further studies are needed to address the knowledge 
gaps identified in this review, with particular emphasis on: (i) 
studies with standardized tools to determine the most effective 
SMA frequencies, durations, and interventions and to closely 
monitor behaviors; (ii) large-scale RCTs of community-based 
populations to clarify the broader applicability of SMAs and 
their short- and long-term clinical and cost outcomes; and 
(iii) quasi-experimental implementation studies which assess 
patient- and provider-centered outcomes to determine the “real-
world” impact of SMAs and to identify potential barriers to their 
successful integration into routine care. Only once such studies 
are widely available will we be able to determine the most effec-
tive and economical form of SMAs, as well as the future role of 
this model of care and its potential for improving outcomes for 
patients with T2DM.
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